Table 4.
Reasons for discontinuation and median time until switch among patients with PSO and PsA who switched biologic therapy
| Switchers (N = 504), n (%) | Time from biologic initiation to switcha, median (IQRb) | |
|---|---|---|
| Reasons for biologic therapy switch | ||
| Effectiveness or safety (n = 426) | ||
| Failure to maintain initial response | 171 (40.1%) | 8.7 (5.7, 14.4) |
| Inadequate initial response | 127 (29.8%) | 5.6 (3.4, 6.7) |
| Alternative MOA | 45 (10.6%) | 6.4 (5.2, 11.7) |
| Active disease | 44 (10.3%) | 11.0 (5.5, 17.8) |
| Side effect (minor and serious) | 35 (8.2%) | 3.8 (2.7, 7.0) |
| Improve tolerability | 3 (0.7%) | 6.7 (–, –) |
| Improve compliance | 1 (0.2%) | 1.8 (–, –) |
| Other reason not related to effectiveness or safety (n = 78) | ||
| Other reasonc | 35 (44.9%) | 6.7 (3.5, 16.6) |
| Patient preference | 21 (26.9%) | 6.8 (5.0, 17.7) |
| Missing reason | 17 (21.8%) | – |
| Fear of future side effect | 3 (3.8%) | 8.3 (–, –) |
| Temporary interruption | 1 (1.3%) | 6.6 (–, –) |
| Drug administration | 1 (1.3%) | 12.8 (–, –) |
COVID-19 Coronavirus disease 2019, IQR interquartile range, MOA mechanism of action
aTime from initiation was measured in months. These quantities are suppressed when sample sizes for each category were < 5
bIQRs are presented as the first and third quartiles
cOther reasons included: denied by insurance, co-pay/patient cost, patient doing well, pregnancy, breastfeeding, COVID-19 concerns, or other